DETROIT The American Red Cross cross has faced many challenges trying to collect sufficient blood in the midst of the COVID-19 pandemic. Once he recovered, he rolled up his sleeve to donate convalescent plasma. But as coronavirus cases in numerous states have spiked, the American Red Cross has seen hospital demand for convalescent plasma surge. We are depleting our COVID-19 plasma inventory faster than we can replace it, said Dr. Pampee Young, Chief Medical Officer with the American Red Cross. To sign up for an appointment, or for more information, visit the official American Red Cross website here.

DETROIT A study from Henry Ford Health system is suggesting theres a benefit to hydroxychloroquine in treating the coronavirus (COVID-19). The study found 13% of people treated only with hydroxychloroquine died, compared to 26.4% who were not treated with hydroxychloroquine. What we think was important in our study, in our patients, is that patients were treated early, Dr. Marcus J. Zervos said. For hydroxychloroquine to have benefit, it has to be given before the patient suffers some of the severe immune reaction that can occur with COVID-19.Officials said 82% of the Henry Ford patients who received hydroxychloroquine received it within 24 hours of admission and 91% within 48 hours. Since the emergency use authorization has been rescinded by the FDA, researchers said hydroxychloroquine is not being used to treat patients in the Henry Ford Health System.

There are more than 130 potential coronavirus (COVID-19) vaccines currently being worked on by researchers around the world. Some of the biggest questions will be answered in the next few weeks as large-scale human trials roll out around the globe. About 8,000 people in the UK have now received the vaccine developed by the University of Oxford. In the UK, volunteers are also testing a vaccine developed by the Imperial College of London. All 24 volunteers given two doses of the vaccine developed higher levels of antibodies than typically seen in recovered patients.

TROY, Mich. – A coronavirus (COVID-19) survivor who spent 94 days in a hospital fighting for her life is finally headed home. Johtasha Mosely was one of the original eight patients with COVID-19 at Beaumont Hospital in Troy. READ: ‘I got my husband back from the dead:’ Man hospitalized for month with COVID-19Mosely was misdiagnosed twice -- and when doctors finally realized she had coronavirus the hospital had run out of ventilators. She was sent to Troy where she was placed on a ventilator for five weeks. Click here to read more coronavirus experiencesWatch the video above for the full report

DETROIT – Study into hydroxychloroquine as a treatment for the coronavirus (COVID-19) has constantly evolved throughout the pandemic, and now, researchers are studying whether the drug can prevent the infection from developing in someone who was exposed to the virus. RECENTLY: New COVID-19 studies raise flags, under auditPreviously published studies have primarily focused on using hydroxychloroquine to treat COVID-19 after someone had already developed the infection, and to date, they have not been conclusive regarding benefit. A new study moved up the process and examined whether hydroxychloroquine can prevent an infection after someone is exposed. ResultsIn the end, there was no significant difference in the number of COVID-19 infections after exposure, and it was concluded that hydroxychloroquine was not found to have a benefit in preventing the development of COVID-19 after exposure. Henry Ford Hospital is still enrolling for the WHIP COVID-19 study of front line workers.

Can hydroxychloroquine prevent infection after exposure to coronavirus (COVID-19)? Published: June 4, 2020, 4:28 pmStudy into hydroxychloroquine as a treatment for the coronavirus (COVID-19) has constantly evolved throughout the pandemic, and now, researchers are studying whether the drug can prevent the infection from developing in someone who was exposed to the virus.

DETROIT Efforts to find a coronavirus (COVID-19) vaccine are about to take another major step forward, though declining cases could actually hamper those efforts. In order to know if a vaccine is actually protecting the people who have been vaccinated, those people need to be exposed to the virus. Researchers cant deliberately expose participants to the coronavirus in clinical trials, so the virus needs to be circulating in the community. Starting this month, Brazil will host the next round of testing on the COVID-19 vaccine being developed by Oxford University and AstraZeneca. Fauci said he is concerned about the durability of that immune response, meaning how long it will last.

DETROIT Weve heard a lot about antibodies in terms of determining who has already been exposed to the coronavirus (COVID-19) and recovered, but many experts believe they could also play a major role in treating the virus. The key to treating the coronavirus might be found in the blood of those who have survived it. I think antibodies will be finished first and will be the bridge toward longer immunity, which will be conferred by vaccines, Crowe said. I think the more groups we have working on it, all the better, and the more shots on goal we have for getting an effective prevention or treatment, Crowe said. Researchers from one company, Regeneron, said their antibody treatment for COVID-19 could be on the market as early as the end of the summer, with many more potentially in the pipeline.

DETROIT – New medications and treatments for coronavirus (COVID-19) are being tested in medical centers across the country. READ: FDA approves plasma therapy treatment for coronavirusHenry Ford Hospital physician Dr. Scott Kaatz took care of some of the first coronavirus patients admitted to the hospital. He was enrolled in the convalescent plasma study while he was being treated at the hospital. “I was unconscious, paralyzed, on a ventilator.”Before he went on the ventilator, Kaatz was able to video chat with his family via Skype. So far 14 coronavirus patients have undergone transfusions of convalescent plasma at Henry Ford.